Study guide

9.5 Dermatologic and Immunologic Conditions in the ICU

Board Certified Critical Care Pharmacist Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pathophysiology and Recognition of Critical Illness

1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness

2 Chapter 2: Medical Devices and Circulatory Support

2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care

3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management

3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation

4 Chapter 4: Vasoactive and Inotropic Therapy in Shock

4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock

5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)

5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness

6 Chapter 6: Cardiovascular Emergencies

6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias

7 Chapter 7: Pulmonary and Infectious Diseases in the ICU

7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU

8 Chapter 8: Neurocritical Care

8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury

9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies

9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy

10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition

10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral

11 Chapter 11: Quality, Safety, and Clinical Guidelines

11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions

12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine

12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management

13 Chapter 13: Treatment Planning and Care Coordination

13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education

9.5 Dermatologic and Immunologic Conditions in the ICU

Key Takeaways Explain This Topic AI

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are dermatologic emergencies requiring immediate withdrawal of culprit drugs (allopurinol, anticonvulsants, sulfonamides, NSAIDs) and supportive burn-unit care; IVIG and corticosteroids remain controversial.

Angioedema from ACE inhibitors may require icatibant (bradykinin B2 antagonist), C1-esterase inhibitor concentrate, or fresh frozen plasma when conventional allergic angioedema therapy fails.

Immunosuppressed ICU patients (transplant, chemotherapy, neutropenia) require broad empiric antimicrobial coverage including antipseudomonal beta-lactam, anti-MRSA, antifungal, and antiviral coverage tailored to risk.

Septic immunosuppression and immunoparalysis after prolonged critical illness predispose to secondary infections and reactivation of latent viruses (CMV, HSV); monitoring and prophylaxis decisions depend on immunosuppression intensity.

Last updated: July 2026

  • Dermatologic and Immunologic Conditions in the ICU
  • Severe Cutaneous Adverse Reactions
  • Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

SJS/TEN are mucocutaneous drug reactions with <10% and >30% body surface area (BSA) epidermal detachment, respectively. Mortality approaches 30% in TEN.

Common culprits: allopurinol, anticonvulsants (lamotrigine, carbamazepine, phenytoin), sulfonamide antibiotics, NSAIDs (oxicam class), nevirapine.

Management:

Immediate withdrawal of all suspect drugs (highest yield intervention).

Burn-unit transfer for TEN >10% BSA; wound care, fluid resuscitation using burn formulas (Parkland), electrolyte monitoring.

Nutritional support (enteral preferred; high protein).

IVIG 2-3 g/kg over 3-4 days historically used; meta-analyses conflicting; not standard of care.

Corticosteroids controversial; brief pulse methylprednisolone may be used early in SJS overlap; avoid in extensive TEN due to infection/sepsis risk.

Cyclosporine 3-5 mg/kg/day for 7-10 days shows some mortality benefit in small studies.

Antibiotic prophylaxis only for documented infection; semi-occlusive dressings with silver sulfadiazine (avoid if sulfonamide allergy).

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

Onset 2-8 weeks after culprit drug (aromatic anticonvulsants, allopurinol, sulfonamides, minocycline). Features: rash, fever, lymphadenopathy, eosinophilia, hepatitis, nephritis.

Treatment: Stop culprit; prednisone 1 mg/kg/day taper over weeks-months; topical corticosteroids. Reactivation of human herpesvirus-6, CMV, EBV contributes; monitor.

Erythema Multiforme Major

Herpes simplex or Mycoplasma-triggered; target lesions; mucosal involvement possible. Treatment: HSV prophylaxis (acyclovir 400 mg BID), supportive care.

Drug-Induced Angioedema

Histamine-mediated (allergic): urticaria + angioedema; responds to epinephrine, H1/H2 blockers, corticosteroids.

Bradykinin-mediated (ACE inhibitor, hereditary/acquired): NO urticaria; does NOT respond to epinephrine or antihistamines.

ACE inhibitor angioedema: Stop ACE inhibitor permanently. For severe airway involvement: icatibant 30 mg SC (bradykinin B2 antagonist), C1-esterase inhibitor concentrate (Berinert 20 IU/kg), fresh frozen plasma 2-4 units, or ecallantide 30 mg SC (kallikrein inhibitor).

Hereditary angioedema: C1-INH concentrate, icatibant; long-term prophylaxis with lanadelumab (300 mg SC q2w) or berotralstat (150 mg PO daily).

  • Immunology in the ICU
  • Immunosuppressed Patient Empiric Coverage

Risk Profile Initial Coverage

Neutropenia (ANC <500) + fever Antipseudomonal beta-lactam (cefepime, piperacillin-tazobactam, meropenem); add vancomycin for catheter-site/soft-tissue suspicion; add antifungal if persistent fever >4-7 days; antiviral if mucositis

Solid organ transplant Tailor to time post-transplant: month 0-1 donor-derived, technical complications; month 1-6 opportunistic (CMV, BK, PJP); >6 months community-acquired; maintain baseline immunosuppression when feasible

HIV/AIDS (CD4 <200) Add coverage for PJP (TMP-SMX), cryptococcus, toxoplasmosis, MAC depending on clinical clues

Corticosteroids (high-dose >20mg prednisone equivalent x2w) PJP prophylaxis if prolonged; watch for Strongyloides hyperinfection in endemic areas

Biologic therapy (TNF inhibitors, rituximab) TB screening, HBV reactivation risk; opportunistic infection coverage per agent

Immunoparalysis and Prolonged Critical Illness

After ~7-10 days of critical illness, monocyte HLA-DR expression drops, marking immunoparalysis. Patients develop secondary infections (fungemia, VAP) and reactivation of latent viruses (CMV, HSV). Strategies:

Monitor trends; consider immune monitoring in transplant recipients.

Avoid prolonged broad-spectrum antibiotics; de-escalate per culture data.

Prophylaxis: acyclovir/valganciclovir per protocol; PJP prophylaxis if prolonged steroids.

Reassess immunosuppressive regimen with transplant team; reduce maintenance doses when safe.

Hypersensitivity Reactions in the ICU

Anaphylaxis: IM epinephrine 0.3-0.5 mg (1:1000) q5-15 min; supine with legs elevated; H1/H2 blockers and corticosteroids adjunctive; fluid resuscitation; bronchodilators. Refractory anaphylaxis may require an IV epinephrine infusion (0.05-0.5 mcg/kg/min) and glucagon (1-5 mg IV over 5 min then 5-20 mcg/min infusion) in beta-blocked patients. Trypsase peaks 1-2 hours; serial levels confirm mast-cell degranulation.

Beta-lactam allergy: Cross-reactivity between penicillin and cephalosporin/carbapenem is low (<2% for third/fourth gen cephalosporins, <1% carbapenems). Use skin testing, graded challenge, or alternative agent per severity.

Vancomycin infusion reaction (red man syndrome): rate-dependent histamine release; slow infusion, antihistamines; not a true allergy (can resume with rate adjustment).

Immune Reconstitution Inflammatory Syndrome (IRIS)

IRIS occurs within days to weeks of starting antiretroviral therapy (HIV), stopping immunosuppression after transplant, or antimicrobial treatment of opportunistic infection. The recovering immune system mounts an exaggerated inflammatory response against latent or subclinical infection (TB, MAC, CMV, cryptococcus, PJP) or self-antigens (sarcoidosis, autoimmune thyroiditis). Presentation: fever, lymphadenopathy, worsening pulmonary infiltrates, meningitis. Treatment is mostly supportive; short-course corticosteroids (prednisone 1-2 mg/kg/day taper) are used for severe inflammatory disease; do not stop ART once started.

Biologic and Targeted Therapy Complications

The ICU increasingly admits patients on biologics (TNF inhibitors, rituximab, anti-IL-6, JAK inhibitors) for autoimmune disease or malignancy. Complications include:

Cytokine release syndrome (CRS): fever, hypotension, hypoxia after CAR-T or blinatumomab; grade by ASTCT criteria; treat with tocilizumab (anti-IL-6) 8 mg/kg IV for grade ≥2, plus corticosteroids for grade ≥3.

Immune checkpoint inhibitor toxicity: ipilimumab, nivolumab, pembrolizumab cause immune-related adverse events (irAEs): pneumonitis, colitis, hepatitis, hypophysitis, myocarditis. First-line is high-dose corticosteroids (methylprednisolone 1-2 mg/kg/day); infliximab or mycophenolate for refractory colitis/hepatitis.

TNF inhibitor infection risk: reactivation of latent TB, HBV, histoplasmosis; screen before initiation.

Rituximab: HBV reactivation risk; prolonged B-cell depletion; PJP prophylaxis if combined with steroids.

Clinical Scenario

A 64-year-old male on lisinopril presents with acute tongue and lip swelling over 6 hours, no urticaria. He has used no new medications. Airways threatened. What pharmacotherapy is indicated?

Answer: This is bradykinin-mediated ACE inhibitor angioedema. Discontinue lisinopril immediately. Administer icatibant 30 mg SC or C1-esterase inhibitor concentrate (Berinert 20 IU/kg IV) ; alternative is fresh frozen plasma 2 units IV . Conventional epinephrine/antihistamines/corticosteroids are ineffective. Prepare for fiberoptic intubation or surgical airway if progression continues.